FDA Approves Genentech ’s Perjeta (Pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer

South San Francisco, CA -- December 20, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin®...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news